Tresiba Receives New Labeling
March 26, 2018 – The U.S. FDA has approved changes to the label for Novo Nordisk’s Tresiba® (insulin degludec). The label will now indicate that Tresiba may reduce the risk of severe hypoglycemia by 40% compared to insulin glargine, and does not increase the risk of adverse cardiovascular events compared to insulin glargine.
The new label may help Tresiba compete against insulin glargine, which is available under the brand names Lantus®, Toujeo®, and Basaglar®, in the U.S. market. Severe hypoglycemia significantly raises the risk of death for patients with type 2 diabetes, and can increase the need for emergency room visits and hospital stays. Tresiba is a long-acting insulin indicated to control blood sugar levels in patients who are at least one month of age.
According to an earnings report released by Novo Nordisk, Tresiba’s annual sales had totaled $800 million by the third quarter in 2017. The drug was launched in February of 2016.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.